A strong portfolio of treatments can improve outcomes for a range of patients and improve product performance by showing a commitment to the therapeutic area. The challenge is to continue to develop products for the same indication without cannibalizing existing products. In this situation, distinct co-positioning is essential to the success of both products. The complexity of multiple brands within the same product portfolio and therapeutic area causes a lack of clarity around the distinction between the appropriate patient type, usage situation, and differentiated benefits for each product if proper co-positioning is not developed. The result may be sub-optimal performance for all the products.
In this paper we share:
S.V.P. Commercial Strategy and Execution
Herspiegel Consulting helps our clients define impactful strategic approaches, streamline launch and commercialization processes, enhance business intelligence, and optimize product performance. Let's talk.
Complete the form to receive this whitepaper.